Prostaglandin E2 mediates cough via the EP3 receptor: Implications for future disease therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 10, 2009, Pages 923-928

  Maher, Sarah A ^a   Birrell, Mark A ^a   Belvisi, Maria G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway sensory nerves; Cough; Prostanoid receptors; Prostanoids; Vagus nerve

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 6 [2 [5 CHLORO 2 (2,4 DIFLUOROBENZYLOXY)PHENYL] 1 CYCLOPENTENYL] 2 PYRIDINECARBOXYLIC ACID; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANTITUSSIVE AGENT; GW 627368X; L 826266; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; RO 3244794; UNCLASSIFIED DRUG; 6 (2 (5 CHLORO 2 (((2,4 DIFLUOROPHENYL)METHYL)OXY)PHENYL) 1 CYCLOPENTEN 1 YL) 2 PYRIDINECARBOXYLIC ACID; 6-(2-(5-CHLORO-2-(((2,4-DIFLUOROPHENYL)METHYL)OXY)PHENYL)-1-CYCLOPENTEN-1-YL)-2-PYRIDINECARBOXYLIC ACID; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; BENZOFURAN DERIVATIVE; CYCLOPENTANE DERIVATIVE; DIMETHYL SULFOXIDE; ISOINDOLE DERIVATIVE; N (2 (4 (4,9 DIETHOXY 1 OXO 1,3 DIHYDRO 2H BENZO(F)ISOINDOL 2 YL)PHENYL)ACETYL)BENZENE SULPHONAMIDE; N-(2-(4-(4,9-DIETHOXY-1-OXO-1,3-DIHYDRO-2H-BENZO(F)ISOINDOL-2-YL)PHENYL)ACETYL)BENZENE SULPHONAMIDE; PROPIONIC ACID DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 3; PTGER3 PROTEIN, HUMAN; PTGER3 PROTEIN, MOUSE; PYRIDINE DERIVATIVE; RO3244794; SULFONAMIDE; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DEPOLARIZATION; DRUG ACTIVITY; GUINEA PIG; HUMAN; MOUSE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY RECEPTOR; VAGUS NERVE;

ANIMALS; BENZOFURANS; COUGH; CYCLOPENTANES; DIMETHYL SULFOXIDE; DINOPROSTONE; GUINEA PIGS; HUMANS; ISOINDOLES; MALE; MICE; MICE, INBRED C57BL; PROPIONIC ACIDS; PYRIDINES; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; SENSORY RECEPTOR CELLS; SULFONAMIDES; VAGUS NERVE; XANTHONES;

EID: 70449528788     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200903-0388OC     Document Type: Article

References (46)

1. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007;55:1-119.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
3. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005;25:1084-1106. (Pubitemid 40823786)
4. Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so SMART? Drug Saf 2006;29:647-656.
5. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172: 149-160.
6. Barnes PJ. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-344. (Pubitemid 30129436)
7. Barnes PJ. New therapies for asthma. Trends Mol Med 2006;12:515-520.
8. Kawakami Y, Uchiyama K, Irie T, Murao M. Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 1973;6:127-132.
9. Walters EH, Bevan C, Parrish RW, Davies BH, Smith AP. Timedependent effect of prostaglandin E2 inhalation on airway responses to bronchoconstrictor agents in normal subjects. Thorax 1982;37: 438-442. (Pubitemid 12090129)
10. Costello JF, Dunlop LS, Gardiner PJ. Characteristics of prostaglandin induced cough in man. Br J Clin Pharmacol 1985;20:355-359.
11. Melillo E, Woolley KL, Manning PJ, Watson RM, O'Byrne PM. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994;149:1138-1141. (Pubitemid 24147051)
12. Pavord ID, Wong CS, Williams J, Tattersfield AE. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90. (Pubitemid 23187223)
13. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999;159:31-36. (Pubitemid 29036499)
14. Coleridge HM, Coleridge JC, Ginzel KH, Baker DG, Banzett RB, Morrison MA. Stimulation of 'irritant' receptors and afferent C-fibres in the lungs by prostaglandins. Nature 1976;264:451-453.
15. Mohammed SP, Higenbottam TW, Adcock JJ. Effects of aerosol-applied capsaicin, histamine and prostaglandin E2 on airway sensory receptors of anaesthetized cats. J Physiol 1993;469:51-66.
16. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-229. (Pubitemid 24185151)
17. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Phys Rev 1999;79:1193-1226. (Pubitemid 29473315)
18. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41:661-690.
19. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prosaglandins Other Lipid Mediat 2002;68-69:535-556.
20. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, Hirose M, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998;246:7-12. (Pubitemid 28413917)
21. Birrell MA, Crispino N, Hele DJ, Patel HJ, Yacoub MH, Barnes PJ, Belvisi MG. Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol 2002;136:620-628. (Pubitemid 34717707)
22. Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesen P, Barnes PJ, Yacoub MH, Belvisi MG. Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. Br J Pharmacol 2003;140:261-268. (Pubitemid 37249185)
23. Belvisi MG, Patel HJ, Freund-Michel V, Hele DJ, Crispino N, Birrell MA. Inhibitory activity of the novel CB2 receptor agonist,GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol 2008;155:547-557.
24. Giblin GMP, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessell IP, Clayton NM, Coleman T, Hall A, Hammond B, et al. The discovery of 6-[2-(5-chloro-2-f[(2,4-difluorophenyl)methyl]oxygphenyl)- 1-cyclopenten-1-yl]- 2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 2007;17:385-389. (Pubitemid 46084909)
25. Gallant M, Carriere MC, Chateauneuf A, Denis D, Gareau Y, Godbout C, Greig G, Juteau H, Lachance N, Lacombe P, et al. Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem Lett 2002;12:2583-2586. (Pubitemid 35245286)
26. Wilson RJ, Giblin GMP, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowshury J, Pritchard S, et al. GW627368X ((N-f2-[4-(4,9- diethoxy-1-oxo-1,3-dihydro-2H-benzo [f]isoindol-2-yl)phenyl]acetylg benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 2003;148:326-339. (Pubitemid 43801180)
27. 2α (FP) receptor. J Pharmacol Exp Ther 1999;290: 1278-1284.
28. Keery RJ, Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol 1988;94:745-754. (Pubitemid 18158894)
29. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985;234:435-441.
30. Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O'Yang C, Smith S, Srinivasan D, Ford APDW, Jett MF. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 2005; 147:335-345. (Pubitemid 43214691)
31. Lalloo UG, Fox AJ, Belvisi MG, Chung KF, Barnes PJ. Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol 1995;79:1082-1087.
32. Fox AJ, Urban L, Barnes PJ, Dray A. Effects of capsazepine against capsaicin- and proton-evoked excitation of single airway C-fibers and vagus nerve from the guinea-pig. Neuroscience 1995;67:741-752.
33. Tilley SL, Hartney JM, Erikson CJ, Jania C, Nguyen M, Stock J, McNeisch J, Valancius C, Panettieri RA Jr, Penn RB, et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol 2003;284:L599-L606. (Pubitemid 36343308)
34. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002;110:651-658. (Pubitemid 34988789)
35. Wilgus TA, Parrett ML, Ross MS, Tober KL, Robertson FM, Oberyszyn TM. Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv Exp Med Biol 2002;507: 85-92.
36. Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol 1999;126:867-872. (Pubitemid 29103702)
37. 2. Am J Physiol Lung Cell Mol Physiol 2001;281:L469-L474.
38. 2 in mice. J Appl Physiol 2000;88: 2214-2218.
39. Martin JG, Suzuki M, Maghni K, Pantano R, Ramos-Barbon D, Ihaku D, Nantel F, Denis D, Hamid Q, Powell WS. The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J Immunol 2002;169:3963-3969.
40. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, Tanaka H, Nagai H, Ichikawa A, Narumiya S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005;6:524-531. (Pubitemid 41716766)
41. Clarke DL, Belvisi MG, Catley MC, Yacoub MH, Newton R, Giembycz MA. Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF. Br J Pharmacol 2004;141:1141-1150. (Pubitemid 38582251)
42. Ratcliffe MJ, Walding A, Shelton PA, Flaherty A, Dougall IG. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-a release from human alveolar macrophages. Eur Respir J 2007;29:986-994.
43. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007;292: L405-L413. (Pubitemid 46271592)
44. Sugiura H, Liu X, Togo S, Kobayashi T, Shen L, Kawasaki S, Kamio K, Wang XQ, Mao LJ, Rennard SI. Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP(2) receptor activation. J Cell Physiol 2007;210:99-110.
45. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 2006;147:707-713.
46. Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose PJ, Williams TJ. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci USA 2007;104:11712-11717. (Pubitemid 47175078)